BioCryst Pharmaceuticals, Inc. (BCRX) financial statements and ratios from SEC XBRL: revenue $874.84M (TTM), net margin 30.2%, revenue growth 94.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $874.84M |
| Net Margin | 30.2% |
| Revenue Growth (YoY) | 94.1% |
| EPS Growth (YoY) | -393.0% |
| FCF Growth (YoY) | -749.0% |
| Price / Sales | 3.58 |
| FCF Yield | -1.2% |
| DCF Value (model) | $20.15 |
| DCF Upside vs Price | 108.2% |
| Altman Z-Score | 2.58 (grey) |
| Piotroski F-Score | 7/9 |
| Sector P/E (Healthcare) | 21.6 |
BCRX overview · BCRX earnings · BCRX KPIs · BCRX investor relations · BCRX ownership · BCRX peers · BCRX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.